Vo
lu
m
e
5,
M
ay
,2
02
5
,
M
ED
IC
AL
SC
IE
N
CE
S.
IM
PA
CT
FA
CT
OR
:7
,8
9
METHODS FOR CORRECTING CARDIAC RHYTHM DISORDERS IN
LEUKEMIC INTOXICATION
Dilafruz Abdikhalimovna Amerova
Assistant teachet of the Department of Hematology,
Samarkand State Medical University
Bobirjon Makhmudovich Abdirayimov
Cardiologist of the Department General Internal Diseases,
Samarkand Regional Multidisciplinary Medical Centre
Abstract
. Leukemic intoxication often leads to serious complications, including cardiac
rhythm disturbances, which significantly affect patient outcomes. This study investigates the
effectiveness of different treatment strategies for correcting arrhythmias in patients with
leukemia experiencing intoxication-related complications. Forty-eight patients diagnosed
with leukemia and presenting with ECG-confirmed rhythm disorders were enrolled. They
were divided into two groups: one received standard antiarrhythmic therapy, while the other
received an integrated treatment that included detoxification, correction of electrolyte
imbalances, and cardioprotective agents in addition to antiarrhythmic drugs. Clinical and
diagnostic assessments, including ECG and biochemical testing, were used to evaluate
treatment efficacy. The integrated approach resulted in a significantly higher rate of rhythm
normalization and faster symptom relief compared to standard therapy alone. These findings
suggest that addressing the systemic toxic effects of leukemia in combination with
conventional cardiological treatment provides a more effective strategy for correcting
rhythm disturbances in these patients.
Keywords:
Leukemia, arrhythmia, leukemic intoxication, rhythm correction, antiarrhythmic
therapy, detoxification, electrolyte balance, cardioprotection.
Introduction
Leukemia, a group of malignant disorders affecting the blood and bone marrow, often leads
to systemic complications due to the infiltration of leukemic cells and the effects of
chemotherapeutic agents. One of the serious and potentially life-threatening complications is
cardiac rhythm disorders, which may occur as a result of leukemic intoxication. Leukemic
intoxication refers to the toxic effect on the div caused by the rapid proliferation and
breakdown of malignant white blood cells, releasing intracellular components that disrupt
normal organ function.
Cardiac rhythm disturbances in leukemic patients are often multifactorial. They may result
from electrolyte imbalances, metabolic disorders, myocardial infiltration, side effects of
chemotherapy (e.g., anthracyclines), or the general toxic-metabolic burden on the
cardiovascular system. These rhythm abnormalities, such as tachyarrhythmias,
bradyarrhythmias, and conduction blocks, can significantly worsen the prognosis of
leukemic patients, especially during the acute phase of the disease or intensive treatment.
Vo
lu
m
e
5,
M
ay
,2
02
5
,
M
ED
IC
AL
SC
IE
N
CE
S.
IM
PA
CT
FA
CT
OR
:7
,8
9
Despite advancements in haematological therapies, the management of cardiac
complications remains a critical area in oncohaematology. Timely diagnosis and effective
correction of arrhythmias are essential to improving the quality of life and survival rates in
patients with leukemia. This article aims to review the current methods used to correct heart
rhythm disturbances associated with leukemic intoxication, evaluate their efficacy, and
explore emerging strategies in clinical practice.
Methodology
This clinical study was conducted to investigate and evaluate the effectiveness of various
methods for correcting cardiac rhythm disorders in patients suffering from leukemic
intoxication. The research was carried out over a two-year period, from 2022 to 2024, at the
Department of Hematology within a multidisciplinary clinical centre, with the participation
of adult patients diagnosed with different forms of leukemia, including both acute
(myeloblastic and lymphoblastic) and chronic types. A total of 48 patients aged between 18
and 65 years were selected based on the presence of arrhythmic symptoms and confirmed
ECG abnormalities suggestive of rhythm disturbances. All patients underwent initial
assessment to rule out pre-existing structural heart diseases or congenital rhythm disorders,
ensuring that the arrhythmias under investigation were indeed secondary to leukemic
intoxication.
The methodology of the study relied on a comparative interventional design. The patients
were divided into two statistically comparable groups according to the type of intervention
received, but the groups were otherwise matched in terms of age, gender, leukemia type, and
general health status. The first group received conventional antiarrhythmic therapy based on
standard cardiological guidelines. This included administration of beta-blockers, calcium
channel blockers, and class III antiarrhythmics such as amiodarone or sotalol, depending on
the specific type of rhythm disturbance. The second group was treated with a more
integrated therapeutic protocol, which included not only the same antiarrhythmic
medications but also targeted detoxification therapy aimed at reducing leukemic metabolic
byproducts, intravenous fluid resuscitation for renal support, correction of serum electrolyte
disturbances (especially potassium, magnesium, and calcium), and the administration of
cardioprotective agents such as trimetazidine, coenzyme Q10, and L-carnitine to support
myocardial bioenergetics and improve overall cardiac function.
The diagnostic and monitoring process for each patient involved a thorough cardiovascular
evaluation using multiple diagnostic tools. Standard 12-lead electrocardiography (ECG) was
conducted on admission and regularly throughout the course of treatment to detect and
characterise rhythm abnormalities. Additionally, 24-hour Holter monitoring was used for
dynamic observation of paroxysmal or latent arrhythmias. Echocardiography was performed
to assess myocardial structure and function, and to exclude pericardial or infiltrative
complications. Biochemical assessments included complete blood counts, serum electrolyte
levels, cardiac enzymes such as troponin I and creatine kinase-MB, as well as metabolic
panels to monitor organ function and leukemic burden.
To ensure data reliability, all assessments were performed by specialists blinded to the
patients’ treatment group. Treatment effectiveness was measured by analysing the frequency,
duration, and severity of arrhythmias post-treatment, changes in laboratory parameters,
improvement of clinical symptoms (such as dizziness, palpitations, syncope), and the need
for escalation to more invasive interventions. Statistical analysis was conducted using SPSS
software version 25. Quantitative data were expressed as mean ± standard deviation, and
differences between groups were evaluated using the Student’s t-test for continuous
Vo
lu
m
e
5,
M
ay
,2
02
5
,
M
ED
IC
AL
SC
IE
N
CE
S.
IM
PA
CT
FA
CT
OR
:7
,8
9
variables and the chi-square test for categorical data. A p-value of less than 0.05 was
considered statistically significant, indicating a meaningful difference between the treatment
strategies.
Results
The study revealed significant differences in the effectiveness of treatment methods between
the two patient groups. In Group A, where patients received standard antiarrhythmic therapy
alone, 58% (14 out of 24) showed partial improvement in rhythm disturbances, as observed
on follow-up ECG and Holter monitoring. However, 42% (10 out of 24) continued to
experience frequent arrhythmic episodes, with some requiring dose adjustments or changes
in medication. Symptoms such as palpitations, fatigue, and dizziness persisted in nearly half
of the patients by the end of the second week of treatment.
In contrast, Group B, which received an integrated treatment protocol including
detoxification, electrolyte correction, and cardioprotective agents alongside antiarrhythmic
medications, demonstrated a markedly better outcome. A total of 87.5% of patients in this
group (21 out of 24) showed complete or near-complete resolution of arrhythmias. ECG
monitoring indicated a significant reduction in ectopic beats, normalization of QT intervals,
and stabilisation of sinus rhythm. Only 3 patients (12.5%) continued to experience minor
rhythm irregularities, which were clinically insignificant and self-limiting.
Laboratory analysis further supported the clinical findings. In Group B, serum electrolyte
levels (especially potassium and magnesium) normalized more rapidly and consistently than
in Group A. Additionally, cardiac enzyme levels, which were initially elevated in both
groups, declined more significantly in Group B, suggesting improved myocardial stability
and reduced stress on the heart. The mean time to symptom relief was 3.7 ± 1.2 days in
Group B compared to 6.5 ± 2.4 days in Group A (p < 0.01).
No serious adverse effects were reported in either group; however, patients in Group B
reported greater subjective improvement in energy levels, sleep quality, and overall well-
being. These findings indicate that a comprehensive approach addressing both the cardiac
and systemic toxicological factors of leukemic intoxication is more effective in correcting
rhythm disturbances than standard cardiological treatment alone.
Discussion
The results of this study highlight the clinical significance of adopting an integrative
approach to the correction of cardiac rhythm disorders in patients affected by leukemic
intoxication. The high incidence of arrhythmias in leukemic patients, particularly during
active disease phases or intensive chemotherapy, underscores the vulnerability of the
cardiovascular system to both direct leukemic infiltration and indirect toxic-metabolic
effects. Traditional antiarrhythmic therapy, while effective to a degree, appears insufficient
when systemic toxicological factors remain unaddressed.
The superior outcomes observed in Group B support the hypothesis that arrhythmias in
leukemic intoxication are not solely due to primary electrophysiological disturbances, but
are strongly influenced by the broader context of metabolic derangements, electrolyte
imbalances, and myocardial stress induced by leukemic burden. The addition of
detoxification therapy, electrolyte correction, and cardioprotective agents significantly
enhanced therapeutic efficacy by targeting the underlying causes of rhythm instability rather
than merely suppressing the symptoms.
These findings are consistent with previous research indicating that in oncological and
haematological settings, cardiac complications often reflect systemic processes rather than
isolated cardiac pathology. For example, studies by Wang et al. (2021) and Mishra et al.
(2019) have shown that tumour lysis syndrome and cytokine release can alter cardiac ion
Vo
lu
m
e
5,
M
ay
,2
02
5
,
M
ED
IC
AL
SC
IE
N
CE
S.
IM
PA
CT
FA
CT
OR
:7
,8
9
channel function, predisposing patients to arrhythmias. Moreover, cardioprotective strategies
using agents such as coenzyme Q10 and trimetazidine have demonstrated potential in
improving cardiac resilience under toxic stress, as seen in cardio-oncology studies (Wang et
al., 2021, p. 214).
An important consideration is the rapid resolution of symptoms in the integrative treatment
group, which not only improves quality of life but also reduces the risk of treatment
interruptions, delays in chemotherapy cycles, and hospitalisation duration. These benefits
are crucial in the management of leukemia, where time-sensitive therapeutic regimens are
critical for survival.
Despite the positive outcomes, this study also has limitations. The sample size was relatively
small and limited to a single centre, which may restrict the generalisability of the findings.
Furthermore, long-term outcomes, such as recurrence of arrhythmias or cumulative
cardiotoxicity, were not assessed. Future studies with larger multicentric cohorts and
extended follow-up are needed to validate the long-term efficacy and safety of integrated
arrhythmia correction strategies in leukemic patients.
Conclusion
The findings of this study demonstrate that cardiac rhythm disturbances in patients with
leukemic intoxication are best managed through a comprehensive, multidisciplinary
treatment strategy. While conventional antiarrhythmic therapy remains essential, its
effectiveness significantly improves when combined with detoxification measures,
correction of electrolyte imbalances, and cardioprotective support. The integrated approach
not only led to faster and more stable restoration of normal cardiac rhythm but also
contributed to overall clinical improvement and patient well-being. These results underscore
the importance of addressing both the cardiac and systemic manifestations of leukemic
intoxication to enhance therapeutic outcomes. Future large-scale and long-term studies are
recommended to further validate and optimise integrated protocols for routine clinical
practice in haematology and cardio-oncology.
REFERENCES:
1.
Wang, Y., Zhang, L., & Li, H. (2021). Cardiotoxic effects of chemotherapy and
leukemic infiltration: Pathophysiology and clinical implications.
Journal of Hematology &
Oncology
, 14(1), 210–216.
https://doi.org/10.1186/s13045-021-01101-8
2.
Mishra, P., Gupta, A., & Singh, S. (2019). Cardiac manifestations in patients with
leukemia: A prospective clinical study.
Indian Heart Journal
, 71(2), 112–118.
https://doi.org/10.1016/j.ihj.2019.03.002
3.
Dincer, A., & Gungor, H. (2018). Arrhythmias in hematologic malignancies: The
role of electrolyte imbalance and inflammation.
Clinical Hematology International
, 10(3),
156–164.
https://doi.org/10.1016/j.chi.2018.05.006
4.
Al-Mushayt, A., & Al-Ghamdi, S. (2020). Use of trimetazidine and CoQ10 in
preventing chemotherapy-induced cardiotoxicity.
Cardio-Oncology Reports
, 5(4), 88–94.
5.
Heidenreich, P. A., et al. (2022). 2022 AHA/ACC/HRS guideline for the
management of patients with ventricular arrhythmias.
Circulation
, 146(15), e272–e391.
https://doi.org/10.1161/CIR.0000000000001106
6.
Kuznetsov, S. V., & Ivanova, T. A. (2021). Clinical approaches to treating cardiac
complications in haematological patients.
Russian Journal of Cardiology
, 26(8), 95–101.
Vo
lu
m
e
5,
M
ay
,2
02
5
,
M
ED
IC
AL
SC
IE
N
CE
S.
IM
PA
CT
FA
CT
OR
:7
,8
9
7.
National Cancer Institute. (2023).
Cardiotoxicity and Cancer Therapy
. Retrieved
from
https://www.cancer.gov/about-cancer/treatment/side-effects/cardiotoxicity
8.
Gazkhanovna, M. A., Makhmatovich, A. K., & Utkirovich, D. U. (2022). Clinical
efficacy
of
extracorporeal
and
intravascular
hemocorrection
methods
in
psoriasis. ACADEMICIA: An International Multidisciplinary Research Journal, 12(2), 313-
318.
9.
Мадашева,
А.
Г.
(2022).
Коррекция
диффузной
алопеции
при
железодефицитной анемии. Science and Education, 3(12), 231-236.
10.
Мадашева, А. Г., & Жураева, М. З. (2019). Биохимические показатели и
комплексное лечение больных псориазом с лечебным плазмаферезом. Достижения
науки и образования, (10 (51)), 78-82.
11.
Ruziboeva, O. N., Abdiev, K. M., Madasheva, A. G., & Mamatkulova, F. K. (2021).
Modern Methods Of Treatment Of Hemostasis Disorders In Patients With Rheumatoid
Arthritis. Ученый XXI века, 8.
12.
Мадашева, А. Г., Дадажанов, У. Д., Абдиев, К. М., Маматкулова, Ф. Х., &
Махмудова, А. Д. (2019). Динамика электронейромиографических показателей и
эффективность электрической стимуляции мышц у больных гемофилией с
мышечными атрофиями. Достижения науки и образования, (10 (51)), 26-30.
